Naistentautien ja synnytysten vastuualue

Julkaisut 2019 (alustava)
Publications 2019 (preliminary)

Lisätietoja julkaisusta saa klikkaamalla sen numeroa.
For full details, please click the number in front of the publication.

1 Aalto A et al. Combination of Treatments With or Without Surgery in Localized Provoked Vulvodynia: Outcomes After Three Years of Follow-Up.
2 Aaltonen R, Nieminen K. Laskeumat.
3 Aittomäki K, Laivuori H. Perinnölliset sairaudet ja geenitestit.
4 Berntsen S et al. The health of children conceived by ART: 'the chicken or the egg.
5 Bhatla N et al. Revised FIGO staging for carcinoma of the cervix uteri.
6 Czamara D et al. Integrated analysis of environmental and genetic influences on cord blood DNA methylation in new-borns.
7 Das P. Transsukupuolisten hormonihoidon seuranta avoterveydenhuollossa.
8 Das P. Transsukupuolisten hormonihoidon seuranta avoterveydenhuollossa.
9 Ekholm E, Laivuori H. Verenpaineongelmat ja pre-eklampsia.
10 Falconer H et al. Robot-assisted approach to cervical cancer (RACC): an international multi-center, open-label randomized controlled trial.
11 González-Martín A et al. Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.
12 Grenman S, Auranen A. Kohdun limakalvon hyperplasia.
13 Grenman S, Auranen A. Kohdun limakalvon polyypit.
14 Grenman S, Auranen A. Kohdun limakalvon ja kohtulihaksen kasvaimet.
15 Grenman S et al. Kohdun limakalvon ja kohtulihaksen kasvaimet.
16 Halttunen-Nieminen M, Ahinko K. Kuukautiskierron häiriöt.
17 Hokkila E et al. The efficacy of misoprostol vaginal insert compared with oral misoprostol in the induction of labor of nulliparous women: A randomized national multicenter trial.
18 Jakobsson M et al. Gynekologiset infektiot.
19 Jääskeläinen T et al. Impact of obesity on angiogenic and inflammatory markers in the Finnish Genetics of Pre-eclampsia Consortium (FINNPEC) cohort.
20 Kalapotharakos G et al. Plasma Heme Scavengers Alpha-1-Microglobulin and Hemopexin as Biomarkers in High-Risk Pregnancies.
21 Kares S et al. HIGH-RISK HPV testing as the primary screening method in an organized regional screening program for cervical cancer: the value of HPV16 and HPV18 genotyping?
22 Karjalainen L et al. Pregnancy-associated stroke -a systematic review of subsequent pregnancies and maternal health.
23 Karjalainen PK et al. The relationship of defecation symptoms and posterior vaginal wall prolapse in women undergoing pelvic organ prolapse surgery.
24 Kazmi N et al. Hypertensive Disorders of Pregnancy and DNA Methylation in Newborns.
25 Kero K, Das P. Transsukupuolisuus.
26 Kiiski J et al. Transverse myocutaneous gracilis flap reconstruction is feasible after pelvic exenteration: 12-year surgical and oncological results.
27 Kiiski J et al. Tranverse myocutaneus gracilis flap reconstruction is feasible after pelvic exenteration: 12-year surgical and oncological results.
28 Kirkinen P. Sikiön rakenneseulonta Suomessa on toimiva ja tuloksikas.
29 Kotaniemi-Talonen L et al. HPV ja kohdunkaulasyövän ehkäisy - missä meillä nyt mennään?
30 Kuismanen K. Synnytys ja sulkijalihasrepeämä.
31 Kuitunen I et al. Pregnancy outcome in women after total hip replacement: A population-based study.
32 Kujansuu E et al. Exposure to sewage water and the development of allergic manifestations in Finnish children.
33 Laasik M et al. Behavior of FDG-avid supradiaphragmatic lymph nodes in PET/CT throughout primary therapy in advanced serous epithelial ovarian cancer: a prospective study.
34 Lagerstedt M et al. Tumor cell-specific Serpin A1 expression in vulvar squamous cell carcinoma.
35 Lauenborg J et al. NFOG guideline: Progesterone for prevention of preterm birth -NORDIC guideline.
36 Locke AE et al. Exome sequencing of Finnish isolates enhances rare-variant association power.
37 Mattsson NK et al. Methods of surgery for pelvic organ prolapse in a nationwide cohort (FINPOP 2015).
38 Mirza MR et al. A phase I study of the PARP inhibitor niraparib in combination with bevacizumab in platinum-sensitive epithelial ovarian cancer: NSGO AVANOVA1/ENGOT-OV24.
39 Mirza MR et al. Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial.
40 Murtoniemi K et al. Longitudinal changes in plasma hemopexin and alpha-1-microglobulin concentrations in women with and without clinical risk factors for pre-eclampsia.
41 Mäenpää J et al. Ulkosynnyttimien, emättimen ja kohdunkaulan kasvaimet .
42 Mäkelä K et al. Oral versus patient-controlled intravenous administration of oxycodone for pain relief after cesarean section.
43 Niemi R. Preoperative Evaluation of Ovarian Tumors.
44 Nieminen P et al. Papilloomavirusinfektiot.
45 Nissinen SI et al. Detection of Pancreatic Cancer by Urine Volatile Organic Compound Analysis.
46 Ovaskainen K et al. Planned home deliveries in Finland, 1996-2013.
47 Pakarinen P et al. Syövän esiasteet.
48 Palomäki O. Äitiyshuolto.
49 Palomäki O. Äitiyshuolto.
50 Ray-Coquard I et al. Final results from GCIG/ENGOT/AGO-OVAR 12, a randomised placebo-controlled phase III trial of nintedanib combined with chemotherapy for newly diagnosed advanced ovarian cancer.
51 Ray-Coquard I et al. Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer.
52 Sova H et al. Hormone profiling, including anti-Müllerian hormone (AMH), for the diagnosis of polycystic ovary syndrome (PCOS) and characterization of PCOS phenotypes.
53 Taavela J et al. Histological, immunohistochemical and mRNA gene expression responses in coeliac disease patients challenged with gluten using PAXgene fixed paraffin-embedded duodenal biopsies.
54 Tabassum R et al. Genetic architecture of human plasma lipidome and its link to cardiovascular disease.
55 Tihtonen K, Uotila J. Synnytyshäiriöt.
56 Toffol E et al. Maternal depressive symptoms during and after pregnancy are associated with poorer sleep quantity and quality and sleep disorders in 3.5-year-old offspring.
57 Toffol E et al. Infant regulatory behavior problems during first month of life and neurobehavioral outcomes in early childhood.
58 Toivonen E, Palomäki O. Synnytyskivun hoito.
59 Toivonen E et al. Perätarjontasynnytys ja sen turvallisuus.
60 Toivonen E et al. Perätarjontaynnytys ja sen turvallisuus.
61 Tähtinen R et al. Long-term risks of stress and urgency urinary incontinence after different vaginal delivery modes.
62 Ukah UVivian et al. Temporal and external validation of the fullPIERS model for the prediction of adverse maternal outcomes in women with pre-eclampsia.
63 Uotila J, Tihtonen K. Synnytysoperaatiot.
64 Veijalainen O et al. Implementation of HPV-based cervical cancer screening in an organised regional screening programme: 3 years of experience.
65 Veskimäe K. High Grade Serous Ovarian Cancer : Expression profiling, aspects of early pathogenesis and potential mechanisms of chemoresistance.
66 Virtanen A et al. Angiogenic capacity in pre-eclampsia and uncomplicated pregnancy estimated by assay of angiogenic proteins and an in vitro vasculogenesis/angiogenesis test.
67 Vuorinen R et al. Sunitinib First-line Treatment in Metastatic Renal Cell Carcinoma: Costs and Effects.
Julkaisutietokanta 31.12.2020 Publications Data Base 31.12.2020